Related Experiment Video
Updated: Mar 26, 2026

A Protocol for Rapid Post-mortem Cell Culture of Diffuse Intrinsic Pontine Glioma DIPG
Published on: March 7, 2017
Oncogenic PI3K mutations are as common as AKT1 and SMO mutations in meningioma
Malak Abedalthagafi1, Wenya Linda Bi1, Ayal A Aizer1
1Department of Pathology, Brigham and Women's Hospital, Boston, Massachusetts (M.A., P.H.M., R.B., M.L.L., S.H.R., R.D.F., K.L.L., A.H.L., S.S.); Department of Pathology, King Fahad Medical City, Riyadh, Saudi Arabia (M.A.); King Abdulaziz City for Science and Technology, Riyadh, Saudi Arabia (M.A.); Harvard Medical School, Boston, Massachusetts (M.A., A.A.A., D.D.-S., P.K.B., D.A.R., P.Y.W., O.A.-M., S.H.R., R.D.F., K.L.L., A.H.L., B.M.A., I.F.D., R.B., S.S.); Department of Neurosurgery, Brigham and Women's Hospital, Boston, Massachusetts (W.L.B., O.A.-M., I.F.D.); Department of Radiation Oncology, Brigham and Women's Hospital, Boston, Massachusetts (A.A.A., B.M.A.); Department of Neurosurgery, Massachusetts General Hospital, Boston, Massachusetts (P.K.A.); Department of Pathology, Massachusetts General Hospital, Boston, Massachusetts (D.D.-S.); Center for Cancer Genomic Discovery, Dana-Farber Cancer Institute, Boston, Massachusetts (A.R.T., P.V.H.); Department of Neuro-Oncology, Massachusetts General Hospital, Boston, Massachusetts (P.K.B.); Center of Neuro-Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts (D.A.R., P.Y.W, R.B.); Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts (K.L.L., R.B.); Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA (S.S.).
Background:
Meningiomas are the most common primary intracranial tumor in adults. Identification of SMO and AKT1 mutations in meningiomas has raised the possibility of targeted therapies for some patients. The frequency of such mutations in clinical cohorts and the presence of other actionable mutations in meningiomas are important to define.
Methods:
We used high-resolution array-comparative genomic hybridization to prospectively characterize copy-number changes in 150 meningiomas and then characterized these samples for mutations in AKT1, KLF4, NF2, PIK3CA, SMO, and TRAF7.
Results:
Similar to prior reports, we identified AKT1 and SMO mutations in a subset of non-NF2-mutant meningiomas (ie, ∼9% and ∼6%, respectively). Notably, we detected oncogenic mutations in PIK3CA in ∼7% of non-NF2-mutant meningiomas. AKT1, SMO, and PIK3CA mutations were mutually exclusive. AKT1, KLF4, and PIK3CA mutations often co-occurred with mutations in TRAF7. PIK3CA-mutant meningiomas showed limited chromosomal instability and were enriched in the skull base.
Conclusion:
This work identifies PI3K signaling as an important target for precision medicine trials in meningioma patients.
Insights
This study found PIK3CA mutations in 7% of meningiomas, suggesting PI3K signaling as a target for precision medicine in brain tumor patients.
Area of Science:
- Neuro-oncology
- Genomics
- Cancer Biology
Background:
- Meningiomas are the most common primary adult brain tumors.
- SMO and AKT1 mutations suggest potential targeted therapies.
- Defining mutation frequencies and actionable targets is crucial.
Purpose of the Study:
- To characterize copy-number changes and mutations in a cohort of meningiomas.
- To identify actionable mutations for targeted therapy development.
- To investigate the role of PI3K signaling in meningioma pathogenesis.
Main Methods:
- High-resolution array-comparative genomic hybridization (aCGH) was used.
- 150 meningioma samples were analyzed for copy-number variations.
- Mutations in AKT1, KLF4, NF2, PIK3CA, SMO, and TRAF7 were characterized.
Main Results:
- AKT1 (∼9%) and SMO (∼6%) mutations were found in non-NF2-mutant meningiomas.
- Oncogenic PIK3CA mutations were detected in ∼7% of non-NF2-mutant meningiomas.
- AKT1, SMO, and PIK3CA mutations were mutually exclusive; PIK3CA-mutant tumors showed low chromosomal instability and were enriched in the skull base.
Conclusions:
- PIK3CA mutations represent a significant finding in meningioma genomics.
- PI3K signaling is identified as a key target for precision medicine in meningioma treatment.
- This research supports the development of targeted therapies for specific meningioma subsets.
More Related Videos
10:13Modeling Astrocytoma Pathogenesis In Vitro and In Vivo Using Cortical Astrocytes or Neural Stem Cells from Conditional, Genetically Engineered Mice
Published on: August 12, 2014
12:52Isolation and Flow Cytometric Analysis of Glioma-infiltrating Peripheral Blood Mononuclear Cells
Published on: November 28, 2015
Related Concept Videos
PI3K/mTOR/AKT Signaling Pathway
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
Cancer-Critical Genes I: Proto-oncogenes
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
Cancer-Critical Genes I: Proto-oncogenes
The Retinoblastoma Gene
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...
The Ras Gene
Ras is a...